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Summary 
Aims: Venous thromboembolism is an important cause of postoperative morbidity and 
mortality in bariatric surgery. Studies of direct oral anticoagulants (DOACs) are not available 
in this surgical field. The objective of this phase 1 clinical trial was to investigate 
pharmacokinetic and pharmacodynamic (PK/PD) parameters of rivaroxaban in bariatric 
patients. 
Methods: In this single-centre study, obese patients received single oral doses of rivaroxaban 
(10 mg) one day before and three days after bariatric surgery. PK and PD parameters were 
assessed at baseline and during 24 hours after drug ingestion.  
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Results: Six Roux-en-Y Gastric bypass patients (RYGB) and 6 Sleeve gastrectomy (SG) 
patients completed the study. Mean rivaroxaban AUC, Cmax, tmax and T1/2 were 971.9 µg·h/L 
(coefficient of variation: 10.6) , 135.3 µg/L (26.7), 1.5 h and 13.1 h (34.1) before and 1165.8 
(10.6), 170.0 (26.7), 1.5 and 8.9 (34.1) post-surgery for SG patients and  933.7 µg·h/L (22.3), 
136.5 µg/L (10.7), 1.5 h und 13.8 h (46.6) before and 1029.4 (22.3), 110.8 (10.7), 2.5 and 15 
(46.6) post-surgery for RYGB patients, respectively. Prothrombin fragments (F1+2) 
decreased during the first 12 hours and increased thereafter in the pre- and the post-bariatric 
setting. Thrombin-antithrombin complexes dropped within one to three hours in the pre-
bariatric setting and remained low after surgery until they increased at 24 hours post-dose. 
Rivaroxaban was well tolerated and no relevant safety issues were observed. 
Conclusions: Bariatric surgery does not appear to alter PK of rivaroxaban in a clinically 
relevant way. Effective prophylactic post-bariatric anticoagulation is supported by changes in 
PD. 
 
WHAT IS KNOWN ABOUT THIS SUBJECT?  
Venous thromboembolism represents a significant cause of morbidity and mortality after 
bariatric surgery. 
Thrombosis prophylaxis with rivaroxaban is established in the perioperative setting of 
orthopaedic patients (hip and knee arthroplasty). 
To date, direct oral anticoagulants (DOACs) have not been systematically investigated in 
bariatric patients. 
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WHAT THIS STUDY ADDS TO OUR KNOWLEDGE? 
This study represents the first systematic PK/PD investigation of prophylactic rivaroxaban 
doses in bariatric patients. 
Single doses of 10 mg rivaroxaban resulted in similar systemic drug exposures before and 
after bariatric surgery, independent of the bariatric procedure performed. 
Effective prophylactic anticoagulation is supported by the pharmacodynamic results of this 
trial. 
 
TABLES OF LINKS  
LIGANDS  
Rivaroxaban 
 
TARGETS  
S1: Chymotrypsin 
Coagulation factor X  
 
These Tables of Links list key protein targets and ligands in this article that are hyperlinked* 
to corresponding entries in http://www.guidetopharmacology.org, the common portal for 
data from the IUPHAR/BPS Guide to PHARMACOLOGY (1), and are permanently archived 
in The Concise Guide to PHARMACOLOGY 2015/16 (2). 
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INTRODUCTION 
The prevalence of obesity as well as morbid obesity is increasing worldwide and therefore 
becoming a growing medical and socioeconomic burden (3-5). Bariatric surgery leads to the 
most sustained reduction of weight and associated co-morbidities, but patients undergoing 
bariatric surgery are at increased risk of venous thromboembolic events (VTE) (6). Obesity is 
an independent risk factor for the development of venous thromboembolism itself and the 
association between obesity and VTE after bariatric surgery is well established (7-9). The 
incidence of symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) ranges 
from 0%-5.4% and 0%-6.4%, respectively, but the true incidence remains uncertain (10). 
Although the overall incidence is low, VTE represents a significant cause of morbidity and 
mortality after surgery. Even with aggressive prophylaxis, VTE cannot be fully prevented 
(11-13). The American Society of Metabolic and Bariatric Surgeons (ASMBS) and the 
American College of Chest Physicians recommend prophylaxis against DVT for all bariatric 
surgery patients (14). Routine prophylactic perioperative use of low-molecular weight 
heparins (LMWHs), intermittent pneumatic compression devices and early mobilization are 
currently the major accepted measures to prevent VTE, particularly in high-risk groups (BMI 
>50 kg/m
2
), advanced age, history of previous VTE, obesity hypoventilation syndrome, open 
and revisional surgery (13, 15). In clinical practice, physicians lack guidelines supporting 
their therapeutic decisions regarding LMWH dosing in the field of bariatric surgery. In 
summary, there exists currently no robust evidence to provide guidance regarding type, dose 
and duration of antithrombotic prophylaxis after bariatric surgery (15). Due to the fact that 
most post-discharge VTE events occur within the first 30 days after surgery, extended VTE 
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prophylaxis should be considered, but the specific duration of chemical prophylaxis is still a 
matter of discussion (12). 
Direct oral anticoagulants (DOACs) are a new class of anticoagulants, whose application is 
more convenient compared to LMWH. DOACs allow effective and safe anticoagulation and 
their monitoring is usually not required. 
Rivaroxaban is the first oral direct factor Xa inhibitor marketed. It was initially approved for 
the prevention of venous thromboembolism in patients after elective hip and knee 
replacement surgery. Rivaroxaban is generally well tolerated and demonstrates a predictable, 
dose-dependent pharmacology profile up to 24 hours after single dose application. The 10 mg 
dose of rivaroxaban has a high oral bioavailability (80-100%) irrespective of food intake, a 
rapid onset of action and the maximum plasma level is achieved two to four hours after oral 
administration (16, 17). Prophylaxis with rivaroxaban had a significantly higher efficacy in 
VTE prophylaxis as compared with enoxaparin after hip and knee replacement surgery with 
similar rates of bleeding (18-21). Friedman et al. compared the efficacy of rivaroxaban in 
orthopaedic surgery patients with BMI >40 kg/m
2
 versus <40 kg/m
2
 (posthoc subanalysis of a 
group of 12,355 patients) and found no difference in the incidence rates of DVT, PE or 
bleedings (22).  Since age, gender or body weight (23) do not seem to alter pharmacokinetics 
(PK) and phamacodynamics (PD) to a clinically relevant degree, the current recommendation 
for prophylaxis is 10 mg rivaroxaban once daily in all patients. 
However, as pointed out in an editorial by S. Duffull (24), rivaroxaban PK/PD studies 
indicate a high degree of between-subject variability in the drug concentration-time profile 
(23). Additionally, the effects of bariatric surgery on PK and PD parameters of DAOCs have 
not been sufficiently investigated to date, and there is no approved dosing recommendation 
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for obese patient in the perioperative setting.  With this clinical trial, we close part of this 
knowledge gap and lay ground for a broader investigation of rivaroxaban in morbidly obese 
patients, especially in the perioperative setting. 
 
METHODS 
This single centre open-label, non-randomized phase 1 clinical trial was designed to 
investigate the single dose PK and PD parameters of rivaroxaban when administered to 12 
patients undergoing a planned bariatric surgical procedure (6 Roux-en-Y-Gastric bypass 
(RYGB) and 6 Sleeve gastrectomy (SG) patients) in the framework of a pilot study. 
The trial was approved by the Independent Ethics Committee of Bern, Switzerland, and the 
Swiss competent authority, Swissmedic. All patients gave written informed consent, and the 
trial was conducted according to the Declaration of Helsinki, the Good Clinical Practice 
guideline and local laws and regulations. The study was registered in the ClinicalTrials.gov 
registry with the identifier number NCT02438098.  
Inclusion and exclusion criteria 
Eligible patients were men and women, 18 years of age or older, with a BMI ≥35 kg/m2 with 
planned elective primary laparoscopic bariatric surgery (RYGB or SG). Main exclusion 
criteria were a history of active bleeding or a high-risk for bleeding, a clinical indication for 
long-term anticoagulation, and evidence of a thrombosis or PE in the personal history. The 
decision to perform bariatric surgery was taken independent of this trial.  
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Study procedure 
Enrolled patients received a single oral dose of 10 mg rivaroxaban (Xarelto
®
, Bayer Pharma 
AG, Germany) one day prior and three days after surgery under non-fasting conditions. 
Venous blood samples were taken to assess the pharmacokinetic and pharmacodynamic 
parameters on both of these days.  Blood samples were taken pre-dose (Baseline) and 1, 2, 3, 
4, 6, 8, 12 and 24 hours post rivaroxaban administration. 
After surgery, use of intermittent pneumatic compression as thrombosis prophylaxis and early 
mobilization were applied as standard of care. LMWH was started postoperatively 6 hours 
after closure of the surgical site provided stable haemostasis had been achieved. Patients with 
BMI <50 kg/m
2
 received 40 mg of subcutaneous enoxaparin (Clexane
®
), those with BMI ≥50 
kg/m
2
 received 60 mg, respectively. Prophylaxis with LMWH was paused on Study Day 3, 
when rivaroxaban was investigated. 
On the 1
st
 postop day, a gastrographin image series was performed to exclude a postoperative 
leak. Patients were discharged on day 4 after the surgical intervention. The last study visit 
occurred at day 30±7, to collect safety data. 
Study endpoints 
Primary study endpoints were the single dose pharmacokinetic parameters of rivaroxaban 
after oral administration before and after RYGB and SG. Secondary endpoints were 
pharmacodynamic parameters as assessed by Thrombin-antithrombin-complexes (TAT), 
Prothrombin fragments 1 and 2 (F1+2) and D-dimers . Safety endpoints were mortality, 
clinically evident proximal or distal DVT, PE and all bleeding events. 
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Sample analysis 
Anti Xa activity of heparins and rivaroxaban was measured using the CE labelled 
chromogenic anti-FXa assay Biophen Heparin 6 (Hyphen BioMed, Neuilly-sur Oise, France). 
This is a one- stage assay that utilizes endogenous antithrombin. It is an automated kinetic 
method during which a constant amount of exogenously added bovine FXa is inhibited by 
anticoagulants in the sample to be tested. Non-inhibited FXa cleaves a FXa-specific 
chromogenic substrate, producing a yellow signal that is detected at 405 nm. The measured 
anti-Xa activity was converted to units anti-Xa/ml (LMWH) or ng/ml (rivaroxaban) by the 
appropriate commercial calibrators, respectively. As for rivaroxaban, the performance of this 
assay has been evaluated against the standard HPLC-MS method and results were 
comparable (25).  
 
Prothrombin time (PT) was performed using Innovin (Siemens, Marburg, Germany) as the 
reagent, the assay was calibrated with a commercial kit containing 4 defined lyophilized 
plasmas (Siemens), the results are the average of duplicate measurements. Activated partial 
thromboplastin time (aPTT) is measured with Pathromtin SL (Siemens), the results are the 
average of duplicate measurements. Coagulation and chromogenic assays were performed on 
a Behring Coagulation System (BCS) and a CS-5100 automated analyzer (Siemens), 
respectively (26). 
 
Prothrombin activation fragments 1+2 (F1+2) and thrombin-antithrombin-complexes (TAT) 
were measured by a quantitative “sandwich” enzyme immunoassay, according to the protocol 
of the manufactures (Enzygnost
® 
TAT micro and Enzygnost
®
 F1+2 micro, Siemens). The 
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absorbance was measured using a microtiter plate reader at 492 nm  (27). D-dimers 
concentrations were determined by an automated quantitative immunoassay, according to the 
manufacturer’s instructions (INNOVANCE® D-dimer, Siemens).  
Safety and tolerability  
Prior to the application of the study drug, every patient received an extensive evaluation 
including clinical chemistry, haematology and coagulation analyses, an electrocardiogram 
and clinical workup. After the application of the study medication, safety and tolerability 
were closely monitored during the first 24 hours by measuring vital signs and specifically 
asking for untoward symptoms. Adverse events were monitored throughout the study to the 
final visit at 30 (±7) days post-operation. Each adverse event (AE) was classified according 
to its severity and seriousness.  
Statistics 
Demographics and relevant baseline variables are summarized for the per protocol (PP) set in 
tabular form. Data are stratified by type of surgery (RYGB, SG). Categorical data are 
presented as frequencies and percentages. For continuous variables, total number of 
measurements, mean and standard deviation are presented. Per protocol, only descriptive 
statistical analyses were foreseen. 
Pharmacokinetic and pharmacodynamics analysis  
Pharmacokinetic parameters were assessed before and after surgery by measuring 
rivaroxaban concentrations at nine different time points: before administration of study 
medication and 1, 2, 3, 4, 6, 8, 12 and 24 h thereafter. Non-compartmental PK parameters 
have been calculated using the R package DescTools (DescTools: Tools for descriptive 
  
 
This article is protected by copyright. All rights reserved. 
statistics. A. Signorelli et al. 2015. R package version 0.99.18, http:// CRAN.R-
project.org/package=DescTools). For the calculation of the AUC, a spline-interpolation was 
used. 
For both surgical procedures, the following pharmacokinetic endpoints are presented: AUC: 
area under plasma concentration curve; Cmax: peak plasma concentration; t1/2: terminal half-
life; Vz/f := (Dose/C0)/bodyweight: apparent volume of distribution during the terminal phase 
divided by total body weight (in kg); tmax: time to peak plasma concentration. For some 
patients tmax could not be determined, since its values were the same for two points of time. 
These measurements were not included in the analysis of tmax. Cmax and tmax are presented in 
tabular and graphical form. 
For D-Dimers (DD), Prothrombin fragments (F1+2) and Thrombin-Antithrombin-Complexes 
(TAT), maximal concentration Cmax and time to maximal concentration tmax is presented in 
tabular form. Two patients (ID 7 before surgery and ID 12 after surgery) are only partially 
included in the analysis since no valid PD results were obtained due to technically difficult 
blood sampling. For the assessment of the pharmacodynamic parameters, measurements at 
the following points of time were used: 0, 1, 3, 12 and 24 h after the application of the study 
medication. PK/PD data were only generated and analysed if the patient in fact received the 
study treatment. 
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RESULTS 
Study population 
Between July 19, 2015 and November 25, 2015, thirteen patients were enrolled into the 
study; one patient was withdrawn before the second application of rivaroxaban for safety 
reasons. Of the remaining 12 patients, 6 patients had SG and 6 patients were treated with 
RYGB surgery. Mean age was 39 years for both groups, and the proportion of male patients 
was 50 and 33% in the SG and in the RYGB group, respectively. Mean BMI was higher in 
the SG group (44.6 kg/m
2
) than in the RYGB group (38.5 kg/m
2
). All patients were of 
Caucasian origin (table 1). 
Pharmacokinetics 
Single application of 10 mg rivaroxaban resulted in a rivaroxaban area under the curve 
(AUC) of of 933.7 g·h/L (prebariatric assessment) and 1029.4 g·h/L (postbariatric) in the 
RYGB group and of 971.9 g·h/L (prebariatric) and 1165.8 (postbariatric) in the SG group, 
respectively. Cmax before bariatric surgery was similar in both groups (136.5 in patients 
RYGB versus 135.3 g/L in SG patients), whereas after the bariatric intervention Cmax was 
lower in RYGB patients (110.8 g/L) and higher in patients after SG (170 g/L). Mean tmax 
was slightly delayed after bariatric intervention in the RYGB group (1.5 versus 2.5 h) but not 
in the SG group (1.5 h). However, the range was similar for both groups and both 
assessments (pre- and postbariatric). Half-life of rivaroxaban was similar in both groups 
before and after bariatric surgery (table 1). PK curves of the two different surgical procedures 
are displayed in figure 1. Pharmacodynamic parameters are summarized in table 2. 
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Pharmacodynamics 
Pharmacodynamic effects of rivaroxaban has been evaluated by the assessment of Thrombin-
antithrombin-complexes (TAT), Prothrombin fragments F1+2 and D-dimers. 
Thrombin-antithrombin-complexes decreased in the preoperative setting within the first one 
to three hours after the application of rivaroxaban. Values significantly dropped within one 
hour from a median TAT concentration of 10.6 to 2.6 and from 13.7 to 2.8 ng/ml for the 
RYGB and the SG group, respectively, and this effect was maintained for at least 12 hours 
after the application of rivaroxaban. After 24 hours, TAT values increased slightly but were 
still lower than those values prior to the application of rivaroxaban for both groups in the 
preoperative setting (figure 2, figure S1, table S1). 
Postoperatively, TAT values were already decreased before the application of rivaroxaban, 
due to the fact that patients received prophylactic low molecular weight heparin the day 
before as part of standard of care. However, a further slight decrease in these values was 
observed both three and twelve hours after the application of rivaroxaban on Study Day 3. 
After 24 h, TAT values increased similar to the increase observed in the assessment taken 
prior to the surgical intervention (figure 2, figure S1, table S1). 
Similar to TAT, F1+2 are characterized by a relevant drop after the application of 
rivaroxaban. Decrease of concentration is most prominent 12 h after the application of 
rivaroxaban (reduction of median F1+2 concentration within 12 hours from 269 to 119 and 
from 212 to 71 pmol/L for the RYGB and the SG group, respectively) whereas values rise 
towards the initial level after 24h (figure 3, figure S2, table S1). The dynamic changes 
observed with F1+2 was similar in the pre- and postoperative setting. 
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D-dimers decrease slightly during the first 12 hours after the application of rivaroxaban 
(reduction of median D-dimers concentrations from 708 to 657 and from 629 to 572 ng/ml 
over 12 hours for the RYGB and the SG group, respectively) and increase to the initial D-
dimer level 24 h after the application of rivaroxaban. In the postoperative setting, D-dimer 
values are generally higher than in the preoperative assessment but the dynamic changes 
observed  are comparable to the preoperative setting (figure 4, figure S3, table S1). 
The pharmacodynamic parameters of two patients with SG (one patients in the presurgical 
and one in the postsurgical group) were excluded from further analysis due to false positive 
values that have been attributed to technical problems during the collection of the blood 
sample. 
Safety and tolerability 
All recorded adverse events and serious adverse events are listed in table 3 together with the 
safety measures taken. There was only one serious adverse event. This patient suffered from a 
jejunal obstruction after RYGB that was unrelated to the study intervention but required 
surgical revision. This patient was withdrawn from the study and from the per protocol 
analysis set. Only in two events, the relationship to the study medication was rated as 
“possible” and both events were assessed as mild and moderate in intensity (table 3). 
 
DISCUSSION 
Single doses of 10 mg rivaroxaban resulted in similar systemic exposures, as measured by 
AUC, both before and after bariatric surgery, regardless of the type of bariatric procedure 
performed. In contrast to what might have been expected, the AUC values of both surgical 
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groups were higher in the postoperative setting, compared to the preoperative setting. 
Maximum concentrations (Cmax) were higher in the SG group postoperatively and lower in 
the RYGB group compared to the pre-surgical assessment. However, this effect is less 
pronounced than what has been observed with different 10 mg galenic formulations of 
rivaroxaban and lies in the expected range of variation of other non-obese patient groups (17, 
28). In the postoperative setting of RYGB patients tmax is slightly delayed, but the range 
remains unaffected. Overall, AUC of 10 mg rivaroxaban in this obese study population 
(before surgery 952.6 μg·h/L, after surgery 1095.5 μg·h/L) was similar to the AUC in healthy 
individuals with normal BMI (1020/14.9 μg·h/L) and patients after total hip replacement 
surgery  (1170 μg·h/L) that have been exposed to the same dose and formulation of 
rivaroxaban supporting the finding that the AUC is not affected in a significant way by 
bariatric surgery (17, 29). 
 
Prophylactic doses of rivaroxaban administered prior to the bariatric surgery led to a rapid 
pharmacodynamic response with a significant (>70%) median decrease of TAT within one 
hour after the exposition to the anticoagulant. In the postoperative groups the initial drop of 
TAT was less pronounced since the patients already received LMWH the day prior to the 
application of rivaroxaban as part of the standard prophylactic treatment. TAT levels 24 
hours after the exposition to rivaroxaban did not return to normal as compared to preoperative 
levels prior to the ingestion of rivaroxaban but to a range observed one to three hours after 
the application of rivaroxaban. 
Additionally, the pharmacodynamic effects as measured by prothrombin activation fragments 
is characterized by a significant (>55%) median drop of F1+2 value within the timeframe of 
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12 hours. After 24 h, prothrombin activation fragments remained below the levels measured 
prior to the administration of rivaroxaban in the preoperative groups, whereas in the 
postoperative group F1+2 levels were equal to the levels measured before the administration 
of rivaroxaban, most likely reflecting the effect of previously administered LMWH. 
The delayed response of F1+2 compared to TAT is explained by its longer half-life (about 90 
min) compared to TAT (about 10 min) (30). For D-dimers, that are characterized by an even 
longer half-life (around 8-12 h), only a slight decrease of concentration could be observed 12 
hours after rivaroxaban ingestion. 
With the exception of baseline levels of F1+2 and particularly TAT, pharmacodynamic 
values in the postsurgical analyses were higher compared to the presurgical investigations as 
consequence of the procoagulant effect of the surgical intervention. This observation may 
indicate that the same dose of anticoagulant is slightly less effective in controlling the 
postoperatively increased procoagulant state. 
Kubitza et al. investigated pharmacokinetics , pharmacodynamics and the safety profile of 10 
mg single dose rivaroxaban administration in different body weight groups. Interestingly, 
AUC values were stable across all weight groups:  1172 µ·h/L in female patients ≤50 kg, 
1029 µ·h/L in patients weighing 70-80 kg, and 1155 µ·h/L in the >120 kg but <150 kg weight 
group. The results of our study indicate, too, that neither increased body weight nor the 
bariatric intervention significantly affect the pharmacokinetic and pharmacodynamics 
parameters of the drug (pre bariatric AUC 952.6 µ·h/L, post bariatric AUC 1095.5 µ·h/L). 
The most probable explanation to this observation is the low volume of distribution of 
rivaroxaban. In fact, rivaroxaban is extensively bound to plasma proteins und has a relatively 
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low tissue affinity (31). In the trial of Kubitza et al. women in the ≤50 kg weight group 
showed an increased Cmax (178 µg/L) whereas rivaroxaban AUCs were similar in all groups. 
Our results demonstrate a higher Cmax (170 µg/L) and an increased inter-individual variability 
of postoperative rivaroxaban plasma levels in the SG group but a slightly decreased Cmax (110 
µ/L) and an increased tmax (plus 1 h, range unaffected) in the RYGB group, again with similar 
AUCs in both surgical groups before and after the bariatric intervention. Reasons for these 
observations may be an increased variability in gastric passage time in patients who had 
bariatric surgery directly affecting the stomach, and alterations in the site of drug absorption 
in RYGB patients as a consequence of the partially bypassed stomach and the bypassed 
duodenum. However, these observations are within the known variations of rivaroxaban 
pharmacokinetic parameters. 
Overall, prophylactic application of rivaroxaban in bariatric patients resulted in 
pharmacokinetic results comparable to those reported from prior trials and the assessment of 
pharmacodynamic parameters supports the clinical effectiveness of a 10 mg rivaroxaban dose 
in obese patients. 
The data obtained from our trial supports these original results and also expands our 
understanding of the clinical pharmacology of rivaroxaban, specifically showing that the 
pharmacokinetic and pharmacodynamic properties remain unaltered after SG and RYGB.  
This clinical trial is the first systematic investigation of rivaroxaban in bariatric surgery 
patients. It shows that there were no relevant alterations in the clinical pharmacology profile 
of rivaroxaban in the postoperative setting compared to results obtained prior to the surgical 
intervention. Single doses of 10 mg rivaroxaban showed an unremarkable safety profile 
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without clinically relevant signs of bleeding after bariatric surgery and there was no 
thrombotic event observed during this clinical trial. 
Limitations of this phase 1 clinical trial are the relatively small sample size and the single 
applications of rivaroxaban. However, it is important to note that rivaroxaban does not have 
significant accumulation after multiple doses, so that the single-dose profile is predictive of 
the multiple dose profile in patients without impaired renal function. 
Another limitation is the short interval between the surgical intervention and the application 
of rivaroxaban. Although this takes into account the timeframe at interest for a prophylactic 
postoperative anticoagulation, it is not known whether pharmacokinetic parameters remain 
unchanged over the following period of weight loss and post-surgical functional adaptations 
of the GI-tract. 
In conclusion, single doses of 10 mg rivaroxaban had a favourable pharmacokinetic, 
pharmacodynamic, and safety profile in this limited bariatric surgery collective. The results 
of this study will help to design larger trials with clinical endpoints in this particular patient 
population with the final goal of safe and efficacious use of rivaroxaban in morbidly obese 
patients. 
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FIGURE LEGENDS 
 
Figure 1 Rivaroxaban concentration: raw data by type of surgery; left Roux-en-Y Gastric 
bypass, right Sleeve gastrectomy 
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Figure 2 Thrombin-Antithrombin-Complexes (TAT) concentrations (median and range, n=6 
RYGB, n=5 SG); left Roux-en-Y Gastric bypass, right Sleeve gastrectomy 
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Figure 3  Prothrombin activation fragments F1+2 concentrations (median and range, n=6 
RYGB, n=5 SG); left Roux-en-Y Gastric bypass, right Sleeve gastrectomy  
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Figure 4  D-Dimers concentrations (median and range, n=6 RYGB, n=5 SG); left Roux-en-Y 
Gastric bypass, right Sleeve gastrectomy 
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Table 1 
 
Sleeve gastrectomy  Roux-en-Y Gastric bypass 
n 6 6 
Age, median (range) 37.7 (24-51) 39.0 (28-51) 
Gender = male (%) 3 (50.0) 1 (16.7) 
Weight median (range) 137.0 (112-153) 101.5 (96-120) 
Height, median (range) 172.5 (167-190) 167.5 (156-171) 
Body mass index, median (range) 44.6 (38.3-50.6) 38.2 (35.4-42.5) 
ASA (%) 
  
 2 1 (16.7) 2 (33.3) 
 3 3 (50) 4 (66.7) 
 4 2 (33.3) 0 (0.0) 
eGFR  (%)   
 71 1 (16.7) 0 (0.0) 
 80 1 (16.7) 1 (16.7) 
 >90 4 (66.7) 5 (83.3) 
Ethnicity = Caucasian (%) 6 (100.0) 6 (100.0) 
Table 1: Baseline characteristics in the per protocol set; ASA: American Society of 
Anesthesiologists physical status classification system; eGFR: estimated glomerular filtration 
rate 
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Table 2 
Patients Parameters Before surgery After surgery 
Ratio before surgery/ 
after surgery 
All patients pooled AUC (µg · h/L) 952.6 / 16.8 1095.5 / 16.8 0.87 [0.77;0.98] 
 
Cmax (µg/L) 135.9 / 19.3 137.3 / 19.3 0.99 [0.79;1.24] 
 
t1/2 (h) 13.5 / 38.8 11.6 / 38.8 1.16 [0.82;1.64] 
 
VZ/f (L/kg) 47.9 / 22.3 44.4 / 22.3 1.08 [0.99;1.18] 
 
Tmax (h) 1.5 (0.9-4) 2 (1-4) NA 
Roux-en-Y Gastric 
bypass AUC (µg · h/L) 933.7 / 22.3 1029.4 / 22.3 0.91 [0.75;1.09] 
 
Cmax (µg/L) 136.5 / 10.7 110.8 / 10.7 1.23 [0.91;1.66] 
 
t1/2 (h) 13.8 / 46.6 15 / 46.6 0.92 [0.57;1.48] 
 
VZ/f (L/kg) 55.3 / 22.5 52.7 / 22.5 1.05 [0.91;1.21] 
 
tmax (h) 1.5 (0.9-4) 2.5 (1-4) NA 
Sleeve gastrectomy AUC (µg · h/L) 971.9 / 10.6 1165.8 / 10.6 0.83 [0.68;1.02] 
 Cmax (µg/L) 135.3 / 26.7 170.0 / 26.7 0.8 [0.59;1.08] 
 t1/2 (h) 13.1 / 34.1 8.9 / 34.1 1.47 [0.82;2.64] 
 VZ/f (L/kg) 41.5 / 9.5 37.4 / 9.5 1.11 [0.95;1.29] 
 tmax (h) 1.5 (1-4) 1.5 (1-4) NA 
Table 2: Pharmacokinetic parameters for all patients (summarized), and Roux-en-Y gastric 
bypass as well as Sleeve gastrectomy  patients (separated); before and after surgery the 
geometric mean and the coefficient of variation is presented. For tmax the median and the 
range is presented. The ratio before surgery/after surgery is presented together with its 95% 
confidence interval.  
AUC area under the plasma-concentration time curve from time 0 to infinity,  Cmax peak 
plasma concentration, t1/2  terminal half-life, Vz/f (Dose/C0)/bodyweight apparent volume of 
distribution during the terminal phase divided by total body weight (in kg),  tmax time to peak 
plasma concentration 
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Table 3 
ID Diagnosis Symptoms AE grade SAE Relationship 
to study drug 
Change of study 
intervention 
1 Head ache Headache mild no unlikely no change 
2 Granuloma liver  mild no unlikely no change 
3 Headache Headache mild no unlikely no change 
3 Koprostase Abdominal pain  mild no unlikely no change 
5 Nausea Nausea mild no unlikely no change 
6 Jejuneal obstruction  Abdominal pain  severe yes unlikely withdrawn 
6 Superficial surgical site 
infection 
 moderate no unlikely no change 
6 Deep surgical site 
infection 
 moderate no unlikely no change 
7 Headache Headache mild no unlikely no change 
8 Headache Headache mild no unlikely no change 
9 Nausea  moderate no unlikely no change 
9 Dizziness  moderate no unlikely no change 
9 Hematoma of abdominal 
wall near incision 
 mild no possible no change 
9 Low Hemoglobin (72 g/L)  moderate no possible no change 
9 Impaired 
oesophagogastral transit 
of gastrographin 
Vomiting mild no unlikely no change 
 
ID Hospitalization 
prolonged 
Drug 
therapy 
 Other action 
taken 
 Death Life 
threatening 
1 no no  no    
2 no no  no    
3 no no  no    
3 no yes metamizole no    
5 no yes metoclopramide no    
6 yes no  yes reintervention  no yes 
6 no no  yes vacuum therapy of 
laparatomy wound 
  
6 no no  yes drainage   
7 no yes paracetamol no    
8 no yes paracetamol no    
9 no yes metoclopramide no    
9 no no  no    
9 no no  no    
9 no yes ferrinject (ferric 
carboxymaltose) 
no    
9 no no  no    
Table 3: Adverse events and safety measures taken; AE adverse event, SAE serious adverse 
event 
